Efficient Inhibition of Pathologic Angiogenesis using Combination Therapy of Anti-Epcam and Anti-VEGFR2 Nanobodies

• Published in: Current pharmaceutical design Vol. 29; no. 13; p. 1059
• Main Authors: Karami, Elmira, Azizi, Parisa, Behdani, Mahdi, Kazemi-Lomedasht, Fatemeh
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2023
• Subjects: Angiogenesis Inhibitors - pharmacology; Angiogenesis Inhibitors - therapeutic use; Animals; Cell Line, Tumor; Cell Proliferation; Human Umbilical Vein Endothelial Cells - metabolism; Humans; Mice; Mice, Nude; Neoplasms - drug therapy; Neovascularization, Pathologic - drug therapy; Signal Transduction; Single-Domain Antibodies - pharmacology; Vascular Endothelial Growth Factor Receptor-2; VEGFR2; cancer; nanobody; EpCAM; angiogenesis; target therapy

EpCAM and VEGFR2 play an important role in angiogenesis and tumorigenesis. It is currently of paramount importance to produce new drugs that can inhibit the angiogenesis and proliferation of tumor cells. Nanobodies are potential drug candidates for cancer therapy due to their unique properties. This...